Inclusion Criteria:~* Ages ≥ 50 and ≤ 85 years~* Informed consent form (ICF) signed by the subject or legally
acceptable representative.~* Clinical diagnosis of dementia due to possible or probable Alzheimer's disease~*
Mini-Mental State Examination score ≥ 16 and ≤ 24 at screening~* If female, postmenopausal for at least 1
year~* Patient living at home, senior residential setting, or an institutional setting without the need for
continuous (i.e. 24-hour) nursing care~* General health status acceptable for participation in the study~*
Fluency (oral and written) in English or Spanish~* If receiving memantine, rivastigmine, galantamine or an
AChEI, receiving a stable dose for at least 3 months (90 days) before screening and with continuous dosing for
at least 3 months. If receiving donepezil, receiving any dose lower than 23 mg once daily.~* The patient is a
non-smoker for at least 12 months.~* The patient or legal representative must agree to comply with the drawing
of blood samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples.~* The patient has a
ratio of total tau/Abeta42 in cerebrospinal fluid ≥ 0.30.~* Patient has a caregiver or legal representative
responsible for administering the drug and recording the time.~
